Buyers often look for potential targets that may be in the process of performing research and development for a new product or products. Those “in-process” research and development (IPR&D) activities can have significant value and, therefore, drive a significant component of the acquisition price. These types of deals are particularly common in the software, technology, and pharmaceutical and life sciences industries.
The M&A Standards significantly changed the accounting for acquired IPR&D. It used to be valued as part of the acquisition and immediately charged to expense, just like ongoing research and development costs. But today acquired IPR&D is generally considered an indefinite-lived asset. This, along with changes in the fair value standards governing how IPR&D is valued, has led to evolving practice with respect to the initial valuation of IPR&D and its subsequent accounting. This edition of Mergers & acquisitions — a snapshot provides an overview of the accounting rules and a glimpse into some of the issues companies face in the accounting and valuation of acquired IPR&D.
© 2016 - 2017 PwC. All rights reserved. PwC refers to the US member firm or one of its subsidiaries or affiliates, and may sometimes refer to the PwC network. Each member firm is a separate legal entity. Please see www.pwc.com/structure for further details.